Research programme: recombinant fusion proteins - Trojantech

Drug Profile

Research programme: recombinant fusion proteins - Trojantech

Alternative Names: Antennapedia Mastermind; Antennapedia Numb; Antennapedia p21; Antennapedia p53; ANTP Notch; ANTP p21; ANTP p53; NTP Mastermind; TR 1; TR 2; TR 3; TR 4

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trojantec
  • Class Antineoplastics; Peptides; Recombinant fusion proteins; Transcription factors; Tumour suppressor proteins
  • Mechanism of Action Apoptosis stimulants; Cell cycle stimulants; Transcription factor stimulants; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
  • 14 Apr 2016 Pharmacodynamic data from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 16 Apr 2015 TR 1 licensed to Sellas Life Sciences Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top